Bivalirudin 250mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bivalirudin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bivalirudin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Bivalirudin on the MHRA register
Bivalirudin 250mg powder for concentrate for solution for infusion vials
Bivalirudin 250mg powder for concentrate for solution for infusion vials
Bivalirudin 250mg powder for concentrate for solution for infusion vials
Angiox 250mg powder for concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Acute coronary syndromes (NG185)
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 27 · Randomised trials: 14 · 1995–2026
Showing the 50 most relevant studies, sorted by most relevant.
Filippo Sanfilippo, Sven Asmussen, Dirk M. Maybauer, et al.
Journal of Intensive Care Medicine, 2016
- Anticoagulants
- Antithrombins
- Heart Failure
Matthew A. Cavender, Marc S. Sabatine
The Lancet, 2014
- Percutaneous Coronary Intervention
- Anticoagulants
- Antithrombins
Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, et al.
The Lancet, 2018
- Femoral Artery
- Anticoagulants
- Antithrombins
A. Lincoff, J. Bittl, R. Harrington, et al.
JAMA, 2003
- Abciximab
- Eptifibatide
- Antibodies, Monoclonal
Adeel Shahzad, Ian Kemp, Christine Mars, et al.
The Lancet, 2014
- United Kingdom
- Heparin
- Hirudins
Gregg W. Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.
The Lancet, 2011
- Angioplasty, Balloon
- Combined Modality Therapy
- Electrocardiography
Roxana Mehran, Alexandra J. Lansky, Bernhard Witzenbichler, et al.
The Lancet, 2009
- Anticoagulants
- Hemorrhage
- Heparin
A. Michael Lincoff
JAMA, 2004
- Hirudins
- Abciximab
- Eptifibatide
Harvey D. White
The Lancet, 2001
- Anticoagulants
- Antithrombins
- Hemodynamics
Yaling Han, Jincheng Guo, Yang Zheng, et al.
JAMA, 2015
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
156 found
Half-life
25 min
Mechanism
Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite.
Food interactions
2 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1mg/k
Half-life
25 min
* Creatinine clearance 10-29mL/min: 57min
* Dialysis-dependant patients: 3.5h
Protein binding
Volume of distribution
0.2L/kg
Metabolism
80%
Elimination
20%
Clearance
3.4 mL/min/kg
* 3.4 mL/min/kg [mild renal function]
* 2.7…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 641 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
* Creatinine clearance 10-29mL/min: 57min
* Dialysis-dependant patients: 3.5h
* 3.4 mL/min/kg [mild renal function]
* 2.7 mL/min/kg [moderate renal function]
* 2.8 mL/min/kg [severe renal function]
* 1 mL/min/kg [Dialysis-dependent patients]
Proteins and enzymes this drug interacts with in the body
PMID:2019570 PMID:21976677
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells PMID:30568593 PMID:9780208
Enzymes involved in drug metabolism — important for understanding drug interactions
Involved compounds
ATC B01AE06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bivalirudin
Additional database identifiers
Drugs Product Database (DPD)
12945
ChemSpider
10482069
BindingDB
50248103
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3535
GenAtlas
F2
GeneCards
F2
GenBank Gene Database
M17262
GenBank Protein Database
339641
Guide to Pharmacology
2362
UniProt Accession
THRB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7218
GenAtlas
MPO
GeneCards
MPO
GenBank Gene Database
J02694
GenBank Protein Database
189040
Guide to Pharmacology
2789
UniProt Accession
PERM_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q4919218), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.